FY2025 EPS Estimates for SLNO Lifted by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald raised its FY2025 earnings estimate for Soleno Therapeutics to ($1.43) per share, significantly up from the previous estimate of ($2.10).
• Soleno Therapeutics reported a quarterly earnings result of ($0.09) per share, surpassing analysts' expectations of ($0.53) by $0.44.
• A majority of analysts have a positive outlook on Soleno, with ten buy ratings and a consensus price target of $113.30.

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Stock analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for shares of Soleno Therapeutics in a research note issued on Thursday, August 7th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($1.43) per share for the year, up from their prior forecast of ($2.10). The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. Cantor Fitzgerald also issued estimates for Soleno Therapeutics' FY2026 earnings at $1.95 EPS.

SLNO has been the subject of several other reports. TD Cowen began coverage on shares of Soleno Therapeutics in a research note on Monday, June 23rd. They set a "buy" rating and a $110.00 price objective for the company. Oppenheimer increased their price target on shares of Soleno Therapeutics from $105.00 to $110.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Wall Street Zen upgraded shares of Soleno Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. Piper Sandler lifted their price target on shares of Soleno Therapeutics from $93.00 to $145.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Finally, Cowen reissued a "buy" rating on shares of Soleno Therapeutics in a research note on Thursday, August 7th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $113.30.

Soleno Therapeutics Trading Down 2.8%

NASDAQ SLNO traded down $2.40 during trading on Monday, hitting $83.36. 991,126 shares of the company's stock traded hands, compared to its average volume of 1,067,542. The stock has a fifty day moving average of $82.98 and a two-hundred day moving average of $68.72. The company has a debt-to-equity ratio of 0.21, a current ratio of 15.13 and a quick ratio of 15.01. Soleno Therapeutics has a 12-month low of $41.50 and a 12-month high of $90.32. The firm has a market cap of $4.43 billion, a P/E ratio of -20.14 and a beta of -2.56.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.44. The firm had revenue of $32.66 million for the quarter, compared to analysts' expectations of $3.91 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SLNO. Ameritas Investment Partners Inc. raised its position in Soleno Therapeutics by 53.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,103 shares of the company's stock valued at $344,000 after purchasing an additional 1,426 shares during the last quarter. Prudential Financial Inc. acquired a new stake in shares of Soleno Therapeutics in the 2nd quarter worth $413,000. Rhumbline Advisers lifted its stake in shares of Soleno Therapeutics by 62.0% in the 2nd quarter. Rhumbline Advisers now owns 59,046 shares of the company's stock worth $4,947,000 after acquiring an additional 22,607 shares during the period. CenterBook Partners LP increased its holdings in shares of Soleno Therapeutics by 49.9% in the 2nd quarter. CenterBook Partners LP now owns 24,512 shares of the company's stock valued at $2,054,000 after purchasing an additional 8,158 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new position in shares of Soleno Therapeutics in the 2nd quarter valued at about $15,617,000. Institutional investors and hedge funds own 97.42% of the company's stock.

Insider Transactions at Soleno Therapeutics

In other news, insider Patricia C. Hirano sold 3,830 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $82.76, for a total value of $316,970.80. Following the sale, the insider directly owned 13,206 shares of the company's stock, valued at approximately $1,092,928.56. The trade was a 22.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.40% of the company's stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.